2 not yet recruiting, 1 completed. 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Not yet recruiting 2, Completed 1 |
Follow Ampullary Carcinoma: new trials by email Literature Review of Ampullary Carcinoma trials Research Report on Ampullary Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase 2 Study of Daraxonrasib in Recurrent KRAS-Mutant Biliary Tract Cancer Daraxonrasib - Biliary Tract Cancers, Intrahepatic Cholangiocarcinoma (Icc) | Phase 2 | Not yet recruiting | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 55 | 2026-11-01 | 2026-08-28 |
| Surufatinib Combined With Toripalimab and AG Regiments for First-line Treatment of Unresectable or Relapsing Metastatic Ampullary Carcinoma Surufatinib+Toripalimab+AG - Ampullary Carcinoma | Phase 2 | Not yet recruiting | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | 30 | 2023-10-01 | 2023-10-02 |
| Vandetanib Gemcitabine Or Placebo Plus Gemcitabine Or Vandetanib Monotherapy In Advanced Biliary Tract Cancer ZD6474, Vandetanib, Gemcitabine, Placebo matching ZD6474 - Biliary Tract Cancer, Gallbladder Cancer | Phase 2 | Completed | Genzyme, a Sanofi Company | 174 | 2008-10-01 | 2016-10-10 |
Biliary Tract Neoplasms (2) · Cholangiocarcinoma (2) · Gallbladder Neoplasms (2) · Carcinoma (1) · Cirrhosis, Familial, with Pulmonary Hypertension (1) · Gastrointestinal Neoplasms (1) · Liver Neoplasms (1) · Neoplasm Metastasis (1)
Adenocarcinoma (2) · Biliary Tract Diseases (2) · Digestive System Diseases (2) · Digestive System Neoplasms (2) · Gallbladder Diseases (2) · Neoplasms (2) · Neoplasms by Histologic Type (2) · Neoplasms by Site (2) · Neoplasms, Glandular and Epithelial (2) · Carcinoma (1) · Gastrointestinal Diseases (1) · Liver Diseases (1) · Neoplastic Processes (1) · Pathologic Processes (1) · Pathological Conditions, Signs and Symptoms (1)
Gemcitabine (1) · vandetanib (1)
Genzyme, a Sanofi Company (1) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (1) · The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School (1)
Italy (1) · United States (1)
Nilo Azad, MD (1)